Product Description
Diethylcarbamazine is an Anthelmintic. Diethylcarbamazine is a N-methylpiperazine and a N-carbamoylpiperazine. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Diethylcarbamazine)
Mechanisms of Action: Arachidonic Acid Metabolism Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Brazil | Canada | France | Greece | India | Indonesia | Ireland | New Zealand | Pakistan | Philippines | Saudi Arabia | Sri Lanka | Taiwan | Thailand | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|